1.1 Heart Failure in Adults

- The starting maintenance dose for digoxin in patients less than 10 years old is based on lean body weight, renal function, and the presence of concomitant products.

1.2 Heart Failure in Pediatric Patients

- The maintenance dose is based on lean body weight, renal function, age, and concomitant products.

1.3 Maintenance Dosing in Adults and Pediatric Patients

- The maintenance dose is based on the lean body weight, renal function, age, and concomitant products.

1.4 Ventricular Fibrillation in Patients with Accessory AV Pathway (Wolff-Parkinson-White Syndrome)

- The maintenance dose is based on the lean body weight, renal function, age, and concomitant products.

2.1 Important Dosing and Administration Information

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

2.2 Loading Dosing Regimens in Adults and Pediatric Patients

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

2.3 Loading Dosing Regimens in Adults and Pediatric Patients Over 10 Years Old

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

2.4 Maintenance Dosing in Pediatric Patients Less Than 10 Years Old

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

2.4.1 Starting and Maintenance Dosing

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

2.5 Maintenance Dosing in Pediatric Patients Over 10 Years Old

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

3.1 Important Dosing and Administration Information

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

3.2 Loading Dosing Regimens in Adults and Pediatric Patients

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

3.3 Loading Dosing Regimens in Adults and Pediatric Patients Over 10 Years Old

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

4.1 Important Dosing and Administration Information

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

4.2 Loading Dosing Regimens in Adults and Pediatric Patients

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

5.1 Ventricular Fibrillation in Patients with Accessory AV Pathway (Wolff-Parkinson-White Syndrome)

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

5.2 Treatment

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

5.3 Maintenance Dosing in Pediatric Patients Less Than 10 Years Old

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

5.4 Maintenance Dosing in Pediatric Patients Over 10 Years Old

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

6.1 Clinical Data Experience

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

6.2 Drug/Laboratory Test Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

6.3 Potentially Significant Pharmacodynamic Drug Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

6.4 Treatment

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

6.5 Switching from Intravenous Digoxin to Oral Digoxin

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

7.1 Use in Specific Populations

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

7.2 Pharmacokinetic Drug Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

7.3 Potentially Significant Pharmacodynamic Drug Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

7.4 Drug/Laboratory Test Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

7.5 Potentially Significant Pharmacodynamic Drug Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

7.6 Treatment

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

8.1 Use in Specific Populations

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

8.2 Drug/Laboratory Test Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

8.3 Potentially Significant Pharmacodynamic Drug Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

8.4 Drug/Laboratory Test Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

8.5 Treatment

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

8.6 Drug/Laboratory Test Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

8.7 Potentially Significant Pharmacodynamic Drug Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

8.8 Drug/Laboratory Test Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

8.9 Treatment

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

8.10 Drug/Laboratory Test Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

9.1 Description

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

9.2 Nonclinical Toxicology

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

9.3 Preclinical Pharmacology

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

9.4 Preclinical Toxicology

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

9.5 Drug Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

9.6 Warnings and Precautions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

9.7 Adverse Reactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

9.8 Contraindications

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

9.9 Black Box Warning

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

9.10 Clinical Pharmacology

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

10.10 Pharmacokinetics

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

10.11 Clinical Pharmacokinetics

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

10.12 Biopharmaceutics

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

11.1 Description

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

11.2 Nonclinical Toxicology

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

11.3 Preclinical Pharmacology

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

11.4 Preclinical Toxicology

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

11.5 Drug Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

11.6 Warnings and Precautions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

11.7 Contraindications

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

11.8 Black Box Warning

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

11.9 Clinical Pharmacology

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

12.1 Description

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

12.2 Nonclinical Toxicology

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

12.3 Preclinical Pharmacology

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

12.4 Preclinical Toxicology

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

12.5 Drug Interactions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

12.6 Warnings and Precautions

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

12.7 Contraindications

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

12.8 Black Box Warning

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.

12.9 Clinical Pharmacology

- The starting dose is based on the lean body weight, renal function, age, and concomitant products.
3.4. Intravenous Administration

**Preparation of Solution**

1. Sterile, nonpyrogenic, water for injection is used to prepare the solution.

2. The volume of reconstitution is 10 mL, 20 mL, or 100 mL, depending on the strength of the solution.

3. The solution is clear and colorless.

**Route of Administration**

The solution is administered intravenously.

**Contraindications**

1. Known allergic reaction to digoxin.

2. Uncontrolled atrial fibrillation.

**Adverse Reactions**

1. Cardiac: Bradycardia, atrioventricular block, heart block, hypotension, hypokalemia, hypomagnesemia, hypothyroidism, supraventricular tachycardia, ventricular arrhythmias, and myocardial ischemia.

2. Noncardiac: Nausea, vomiting, diarrhea, anorexia, weight loss, fever, headache, dizziness, agitation, confusion, disorientation, anxiety, somnolence, myalgia, arthralgia, rash, pruritus, urticaria, angioedema, and anaphylaxis.

**Precautions**

1. Monitor cardiac rhythm and function, especially in patients receiving concomitant medications that may affect cardiac function.

2. Continue monitoring if digoxin concentrations exceed therapeutic range.

3. Caution should be exercised when concomitantly administering digoxin with other drugs that may increase or decrease its serum concentration.

4. Patients with renal impairment or those taking diuretics may require a lower maintenance dose.

5. Patients with hepatic disease or those receiving medication that can affect digoxin metabolism may require a lower maintenance dose.

**Dose Calculation**

1. Calculate the dose based on age, weight, and renal function.

2. Adjust the dose based on patient response and serum digoxin concentrations.

**Special Populations**

1. Children: The usual maintenance dose range is 0.5 to 2 mcg/kg/day.

2. Elderly patients: The usual maintenance dose range is 0.5 to 1 mcg/kg/day.

3. Renal failure: The usual maintenance dose range is 0.5 to 1 mcg/kg/day.

**Table 1: Times to Onset of Pharmacologic Effect and to Peak Effect of Preparations of DIGOXIN**

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Onset of Effect</th>
<th>Peak of Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>2-4 hours</td>
<td>2-4 hours</td>
</tr>
<tr>
<td>Intravenous</td>
<td>0.5-1 hours</td>
<td>0.5-1 hours</td>
</tr>
</tbody>
</table>

**References**


